Edition:
India

Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

307.35USD
14 Aug 2020
Change (% chg)

$-1.02 (-0.33%)
Prev Close
$308.37
Open
$307.48
Day's High
$310.60
Day's Low
$304.33
Volume
93,211
Avg. Vol
181,016
52-wk High
$318.73
52-wk Low
$119.46

Summary

Name Age Since Current Position

Michael Minogue

53 2005 Chairman of the Board, President, Chief Executive Officer

Todd Trapp

49 2018 Chief Financial Officer, Vice President

David Weber

58 2007 Chief Operating Officer, Senior Vice President

Marc Began

53 2018 Vice President, General Counsel, Secretary

Michael Howley

56 2009 Vice President and General Manager, Global Sales

Andrew Greenfield

47 2019 Vice President, Chief Commercial Officer

Dorothy Puhy

68 2005 Lead Independent Director

Jeannine Rivet

72 2016 Independent Director

Eric Rose

69 2014 Independent Director

Martin Sutter

65 2008 Independent Director

Paul Thomas

64 2011 Independent Director

Christopher Van Gorder

67 2016 Independent Director

Biographies

Name Description

Michael Minogue

Mr. Michael R. Minogue serves as Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Michael R. Minogue has been Chairman, President and Chief Executive Officer of ABIOMED, Inc. since 2004. Mr. Minogue transitioned the Company’s mission to creating the field of heart recovery with the acquisition and development of new technologies such as the Impella®, the world’s smallest heart pump, and extracorporeal membrane oxygenation (ECMO). ABIOMED has been one of the fastest growing, GAAP profitable medtech companies and ranked the third best performing stock on the S&P 500 for the last decade. ABIOMED has earned numerous global regulatory approvals on new products and indications in the United States, Europe, Japan and other countries. ABIOMED employs approximately 1,500 people with facilities in Danvers, Massachusetts, Aachen and Berlin, Germany and Tokyo, Japan. In addition to his responsibilities at ABIOMED, Mr. Minogue currently serves on the medical device industry association board of directors for AdvaMed, and serves on the board for the Medical Device Innovation Consortium (MDIC). He also serves on Insulet Corporation’s Board of Directors and was on the boards of LifeCell and Bioventus.

Todd Trapp

Mr. Todd A. Trapp serves as Chief Financial Officer, Vice President of the Company. Mr. Trapp was appointed as our Vice President and Chief Financial Officer on April 9, 2018. He currently oversees the Finance, IT and Human Resources functions. From April 2015 to March 2018, Mr. Trapp served as Chief Financial Officer of Watts Water Technologies, Inc., where he was responsible for the global finance and IT operations. Prior to joining Watts Water Technologies, Mr. Trapp spent 13 years in a variety of financial and operational roles at Honeywell International Inc., including as Vice President of Global Financial Planning and Analysis, Chief Financial Officer of the Airlines Business Unit, Director of Finance for the Transportation Systems Business Group, Investor Relations Manager and other finance management positions. Prior to joining Honeywell, Mr. Trapp held several treasury and finance operational roles at United Business Media, Inc. and Pearson Inc. Mr. Trapp received his Bachelor of Science in Accounting from Providence College and his Master of Business Administration in Finance from Northeastern University. He is also Six Sigma Green Belt certified.

David Weber

Dr. David M. Weber Ph.D. serves as Chief Operating Officer, Senior Vice President of the Company. Prior to joining us, Dr. Weber served as General Manager, Aviation Business at GE Security - Homeland Protection from April 2005 until April 2007 where he led GE Security’s Aviation and Transportation Business and was responsible for product development, marketing and sales. From June 2004 until April 2005, he served as General Manager, MRI Marketing at GE Healthcare where he was responsible for strategic product planning, go-to-market and product launch activities, including developing product roadmaps and introducing new product technologies to the market, and from March 2001 until June 2004, he served as Manager, Global High Field MRI Business, GE Medical Systems where he was responsible for new product planning and development. Dr. Weber received his Bachelor of Science in Physics from Denison University, his Bachelor of Science in Nuclear Engineering from Columbia University, his Master of Science in Medical Physics from the University of Wisconsin and his Doctor of Philosophy in Medical Physics from the University of Wisconsin.

Marc Began

Mr. Marc A. Began serves as Vice President, General Counsel, Secretary of the Company. Mr. Began joined us in June 2018 and serves as our Vice President, General Counsel, and Secretary responsible for leading the Company’s legal, compliance and business development functions worldwide. Mr. Began joined us from Boehringer Ingelheim where he was Vice President of intellectual property responsible for medical device, pharmaceutical, and biologic intellectual property issues. Before joining Boehringer Ingelheim, Mr. Began held various positions of increasing responsibility at Novo Nordisk during a 15-year period. Before joining Novo Nordisk, Mr. Began was an associate at the law firms of Sullivan & Cromwell LLP and White & Case LLP in New York, where he handled a broad range of legal matters, including litigation, intellectual property, corporate transactions, regulatory and compliance. Mr. Began earned a Juris Doctor degree from Albany Law School at Union University and holds a Bachelor of Science degree in mechanical engineering from Rensselaer Polytechnic Institute.

Michael Howley

Mr. Michael G. Howley serves as Vice President and General Manager, Global Sales of the Company. Prior to joining us, Mr. Howley spent 20 years at GE Healthcare. From February 2006 to February 2009, he was General Manager at GE Healthcare, overseeing the Americas X-ray and Interventional Radiology division. From April 2004 to February 2006, Mr. Howley held the General Manager position for the Clinical Information Systems at GE. From October 2002 to April 2004, he was the Americas Sales Manager of Functional and Molecular Imaging. Prior to this role, Mr. Howley held several other national and regional sales positions at GE, beginning in 1989. Mr. Howley received his Bachelor of Science in Business Administration and Marketing from Auburn University.

Andrew Greenfield

Mr. Andrew J. Greenfield serves as Vice President, Chief Commercial Officer of the Company. Mr. Greenfield was appointed as our Vice President and Chief Commercial Officer in April of 2019. He joined us in 2005 and prior to this recent appointment, served as Vice President and General Manager, Global Marketing. In addition to overseeing our global commercial operations, Andrew oversees government affairs, reimbursement, global marketing, Asia Pacific and physician programs. Before joining us, Mr. Greenfield held positions in sales, marketing and finance at GE Healthcare including consulting with large U.S. health systems, eCommerce and Six Sigma from 1999 to 2005. Prior to GE Healthcare, he held positions in sales, marketing and finance at The Boeing Company, including European Country Manager, and is a graduate of the Fiscal Development Program. He received his Bachelor Degree in Finance from the University of Illinois and his Master of Business Administration degree from St. Louis University. Mr. Greenfield also holds a Master Blackbelt in Six Sigma and Change Acceleration Process certification from GE.

Dorothy Puhy

Ms. Dorothy E. Puhy serves as Lead Independent Director of the Company. Ms. Puhy served as Executive Vice President and Chief Operating Officer for the Dana-Farber Cancer Institute from 2012 until her retirement in March 2019. Ms. Puhy previously served as the Chief Financial Officer of the Dana-Farber Cancer Institute from 1994 to 2012 and as its Assistant Treasurer from 1995 to 2012. From 1985 to 1994, Ms. Puhy held various financial positions at the New England Medical Center Hospitals, Inc., including Chief Financial Officer from 1989 to 1994. Ms. Puhy received her Bachelor of Arts from the University of Pennsylvania and her Master of Business Administration from the Wharton School of Business at the University of Pennsylvania.

Jeannine Rivet

Ms. Jeannine M. Rivet serves as Independent Director of the Company. Ms. Rivet served as Executive Vice President of UnitedHealth Group from 2001 until her retirement in December 2018. Previously, she served as Chief Executive Officer of UnitedHealthcare from 1998 to 2001, Chief Executive Officer of Ingenix from 2001 to 2003 and Chief Executive Officer of Optum from December 2003 to 2005. Ms. Rivet received her Bachelor of Science in Nursing from Boston College and her Master’s Degree in Public Health from Boston University. She also worked as a registered nurse for several years prior to entering the managed care business.

Eric Rose

Dr. Eric A. Rose M.D. serves as Independent Director of the Company. Dr. Rose serves as Chairman of SIGA Technologies, Inc. (“SIGA”), a developer of antiviral drugs directed at potential agents of bioterror. SIGA successfully developed a cure for smallpox, which is now in the strategic national stockpile of the United States government. The company has received more than $600 million in contract revenue and research support from the United States Biomedical Advanced Research and Development Authority. The company filed voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in September 2014 and exited from bankruptcy protection in April 2016. Dr. Rose served from 2007 to 2016 as Executive Vice President for Life Sciences at MacAndrews & Forbes and Chief Executive Officer and Chairman of SIGA. Dr. Rose chaired the Department of Health Evidence & Policy at the Mount Sinai School of Medicine from 2008 to 2013, where he now serves as professor. From 1994 to 2007, he was Surgeon-in-Chief at New York-Presbyterian Hospital/Columbia and Chairman of the Department of Surgery at the Columbia University College of Physicians and Surgeons. A heart surgeon, researcher and entrepreneur, Dr. Rose helped grow Columbia’s Department of Surgery over 25 years while investigating, managing and developing complex medical technologies. He has authored or co-authored more than 300 scientific publications and has received more than $25 million in NIH support for his research. Dr. Rose pioneered heart transplantation in children, performing the first successful pediatric heart transplant in 1984, and has investigated many alternatives to heart transplantation, including cross-species transplantation and man-made heart pumps.

Martin Sutter

Mr. Martin P. Sutter serves as Independent Director of the Company. Mr. Sutter has been the Co-Founder and a Managing Director of EW Healthcare Partners, previously known as Essex Woodlands Health Ventures, a healthcare-focused growth equity firm. Educated in chemical engineering and finance, Mr. Sutter has more than 35 years of management experience in operations, marketing, finance and venture capital. Mr. Sutter holds a Bachelor of Science degree from Louisiana State University and a Master of Business Administration from the University of Houston.

Paul Thomas

Mr. Paul G. Thomas serves as Independent Director of the Company. Mr. Thomas co-founded Prominex, Inc., a start-up company focused on the development of molecular diagnostic assays for point-of-care infectious disease testing. Mr. Thomas currently serves as Prominex’s Chief Executive Officer. Prior to his employment with Prominex, Mr. Thomas served as the founder, President, Chief Executive Officer and director of Roka Bioscience, Inc. from September 2009 until his retirement in January 2017. Previously, he served as President, Chief Executive Officer and Chairman of LifeCell from October 1998 until its acquisition by Kinetic Concepts. Prior to joining LifeCell, Mr. Thomas held various senior positions, including President of the Pharmaceuticals division, during a 15-year tenure with Ohmeda Inc. Mr. Thomas received his Bachelor of Science in Chemistry from St. Michael’s College and his Master of Business Administration from Columbia University, and completed his postgraduate studies in chemistry at the University of Georgia.

Christopher Van Gorder

Mr. Christopher D. Van Gorder serves as Independent Director of the Company. Mr. Van Gorder has been President, Chief Executive Officer and a director of Scripps Health, where he oversees all functions of the integrated health system. Mr. Van Gorder currently is a clinical professor of health practice at the University of Southern California Price School of Public Policy, where he also serves on the board of councilors. Mr. Van Gorder received his undergraduate degree from California State University, Los Angeles, and his master’s degree in public administration/health services administration from the University of Southern California. He has also completed the Chief Executive Officer Program at the Wharton School of Business at the University of Pennsylvania.

Basic Compensation

Name Fiscal Year Total

Michael Minogue

16,612,800

Todd Trapp

3,073,190

David Weber

2,662,040

Marc Began

--

Michael Howley

1,706,800

Andrew Greenfield

2,819,600

Dorothy Puhy

294,996

Jeannine Rivet

267,496

Eric Rose

259,996

Martin Sutter

267,496

Paul Thomas

269,996

Christopher Van Gorder

264,996
As Of  31 Mar 2020